Twist Bioscience Corporation Debt Securities, Available-for-sale, Amortized Cost
Twist Bioscience Corporation (TWST) had Debt Securities, Available-for-sale, Amortized Cost of $49.44 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-03
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $49.44M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $49.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $49.27M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $49.32M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $49.44M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $49.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $49.27M 10-Q/A · filed 2026-02-26 |
| 2025-09-30 | $49.32M 10-Q · filed 2026-08-03 |
| 2025-06-30 | $49.43M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $46.69M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $49.37M 10-Q · filed 2025-02-03 |
| 2024-09-30 | $49.96M 10-K · filed 2025-11-17 |
| 2023-09-30 | $50.03M 10-K · filed 2024-11-18 |
| 2021-09-30 | $12.03M 10-K · filed 2021-11-23 |
| 2020-09-30 | $196.32M 10-K · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |